Thomas Willis醫(yī)生 (1621-1675) 希臘醫(yī)生第一次使用Diabetes這個詞來描述尿多癥。直到1675年,,英國醫(yī)生Thomas Willis才正式運用Diabetes Mellitus描述糖尿病。 Diabetes mellitus (DM) comprises a group of metabolic disorders that share the common phenotype of hyperglycemia. DM is currently classified on the basis of the pathogenic process that leads to hyperglycemia. Diagnosis A person is considered to be diabetic if he or she has one or more of the following: ●Symptoms of diabetes and a random blood sugar of 200 mg/dL (11.1 mmol/L) or higher ●A fasting blood sugar level of 126 mg/dL (7.0 mmol/L) or higher ●A blood sugar of 200 mg/dL (11.1 mmol/L) or higher two hours after an oral glucose tolerance test ●An A1C of 6.5 percent or higher The blood tests must be repeated on another day to confirm the diagnosis of diabetes. Two intermediate categories have also been designated: · Impaired fasting glucose (IFG) for a fasting plasma glucose level of 5.6– 6.9 mmol/L (100–125 mg/dL) Clinical features polyuria, polydipsia, weight loss, fatigue, weakness, blurred vision, frequent superficial infections, and poor wound healing. Acute complications of DM:Diabetic ketoacidosis (DKA),,Hyperglycemic hyperosmolar state The chronic complications of DM : · Ophthalmologic: nonproliferative or proliferative diabetic retinopathy, macular edema · Renal: proteinuria, end-stage renal disease (ESRD), type IV renal tubular acidosis · Neurologic: distal symmetric polyneuropathy, polyradiculopathy, mononeuropathy, autonomic neuropathy Diabetes Mellitus Optimal treatment of DM requires more than plasma glucose management.Comprehensive diabetes care should also detect and manage DM-specific complications and modify risk factors for DM-associated diseases. The pt with type 1 or type 2 DM should receive education about nutrition, exercise,care of diabetes during illness, and medications to lower the plasma glucose. Insulin Short-acting (Lispro,Regular,Aspart) Long-acting(NPH,Detemir,Glargine) Insulin combination Oral glucose-lowering agents Biguanide Metformin Sulfonylurea Glimepiride Non-sulfonylurea secretagogue Repaglinide A-glucosidase inhibitor Acarbose
|
|